Close

Aegis Capital Affirms Advaxis (ADXS) at 'Buy'; MedImmune Agreement Could Open Doors to More Licensing

July 22, 2014 11:12 AM EDT Send to a Friend
Aegis Capital affirms Advaxis, Inc. (Nasdaq: ADXS) at Buy with a target price of $15 following news that the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login